<DOC>
	<DOCNO>NCT02629172</DOCNO>
	<brief_summary>The main objective study evaluate safety effectiveness paritaprevir/ritonavir/ombitasvir use patient infected HCV genotype 1 daily practice Japan .</brief_summary>
	<brief_title>Drug Use-results Survey Patients Infected With Hepatitis C Virus Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>HCV genotype 1 patient treated paritaprevir/ritonavir/ombitasvir daily practice Patients previously treat paritaprevir/ritonavir/ombitasvir</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Genotype 1</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Hepatitis C Virus ( HCV )</keyword>
	<keyword>Ombitasvir</keyword>
	<keyword>Paritaprevir</keyword>
</DOC>